Wutah dodolan YoY (TTM): Evoke Pharma Inc (EVOK)

Logo grafis Evoke Pharma Inc (EVOK)

Evoke Pharma, Inc. (EVOK) has pivoted to the commercialization of its Gimoti spray, leveraging a contract network to expand margins without incurring capital expenditures. However, debt obligations and insurance complexities create risks in the event of weak demand. The current focus has shifted toward product support with minimal R&D. Analyzing the chart on GURU.Markets, we see that the rolling annual revenue growth from sales confirms this data, where 67.70 records a new level mark.

Wutah pendapatan YoY sajrone 12 wulan kepungkur Evoke Pharma Inc. (EVOK): kanggo periode 11.02.2024 - 27.12.2025

Evoke Pharma (EVOK) - rincian metrik lan laporan keuangan

- nilai pasar lan prakiraan target analis:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:EVOK (Evoke Pharma Inc)
Produk dadi evokepharma.com

For Evoke Pharma, Inc. (EVOK), the TTM annual revenue growth rate on the GURU.Markets platform serves as an indicator of commercial expansion amid geopolitical instability and supply chain disruptions. This metric calculates the relative change in revenue over a rolling 12-month period, allowing investors to assess sales resilience and promptly identify the fading of growth drivers against a backdrop of shrinking target markets.